{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:18:15Z","timestamp":1793906295592,"version":"4.8.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 A107613"],"award-info":[{"award-number":["T32 A107613"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-025-00731-6","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:31:25Z","timestamp":1740022285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Update on Vaccination Recommendations for Adults with HIV"],"prefix":"10.1007","volume":"22","author":[{"given":"Fiona","family":"Gispen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"731_CR1","doi-asserted-by":"publisher","first-page":"101471","DOI":"10.1016\/j.smim.2021.101471","volume":"51","author":"CW Cai","year":"2021","unstructured":"Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. Semin Immunol. 2021;51:101471. https:\/\/doi.org\/10.1016\/j.smim.2021.101471.","journal-title":"Semin Immunol"},{"issue":"2","key":"731_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/infdis\/jiz678","volume":"222","author":"A Thomas","year":"2019","unstructured":"Thomas A, Hammarlund E, Gao L, Holman S, Michel KG, Glesby M, et al. Loss of Preexisting Immunological Memory Among Human Immunodeficiency Virus-Infected Women Despite Immune Reconstitution With Antiretroviral Therapy. J Infect Dis. 2019;222(2):243\u201351. https:\/\/doi.org\/10.1093\/infdis\/jiz678.","journal-title":"J Infect Dis"},{"issue":"25","key":"731_CR3","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1182\/blood-2010-05-285528","volume":"116","author":"S Moir","year":"2010","unstructured":"Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010;116(25):5571\u20139. https:\/\/doi.org\/10.1182\/blood-2010-05-285528.","journal-title":"Blood"},{"issue":"4","key":"731_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/qai.0000000000000869","volume":"71","author":"LN Abudulai","year":"2016","unstructured":"Abudulai LN, Fernandez S, Corscadden K, Hunter M, Kirkham LA, Post JJ, et al. Chronic HIV-1 Infection Induces B-Cell Dysfunction That Is Incompletely Resolved by Long-Term Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2016;71(4):381\u20139. https:\/\/doi.org\/10.1097\/qai.0000000000000869.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"731_CR5","doi-asserted-by":"publisher","first-page":"661990","DOI":"10.3389\/fimmu.2021.661990","volume":"12","author":"L Van de Wijer","year":"2021","unstructured":"Van de Wijer L, van der Heijden WA, Ter Horst R, Jaeger M, Trypsteen W, Rutsaert S, et al. The Architecture of Circulating Immune Cells Is Dysregulated in People Living With HIV on Long Term Antiretroviral Treatment and Relates With Markers of the HIV-1 Reservoir, Cytomegalovirus, and Microbial Translocation. Front Immunol. 2021;12:661990. https:\/\/doi.org\/10.3389\/fimmu.2021.661990.","journal-title":"Front Immunol"},{"key":"731_CR6","doi-asserted-by":"publisher","first-page":"102186","DOI":"10.1016\/j.coi.2022.102186","volume":"76","author":"MA Boyd","year":"2022","unstructured":"Boyd MA, van Bockel D, Munier CML, Kelleher AD. Navigating the complexity of chronic HIV-1 associated immune dysregulation. Curr Opin Immunol. 2022;76:102186. https:\/\/doi.org\/10.1016\/j.coi.2022.102186.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"731_CR7","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/qad.0000000000002881","volume":"35","author":"V Mercurio","year":"2021","unstructured":"Mercurio V, Fitzgerald W, Vanpouille C, Molodtsov I, Margolis L. Mechanisms of residual immune activation in HIV-1-infected human lymphoid tissue ex vivo. AIDS. 2021;35(8):1179\u201390. https:\/\/doi.org\/10.1097\/qad.0000000000002881.","journal-title":"AIDS"},{"key":"731_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/B978-0-323-85415-3.00015-5","volume-title":"Translational Autoimmunity","author":"LR Ruperto","year":"2022","unstructured":"Ruperto LR, Arenzana CB, Marhuenda AR, Bernardino JI. Chapter 7 - Autoimmunity and HIV infection. In: Rezaei N, editor. Translational Autoimmunity. Academic Press; 2022. p. 141\u201367."},{"issue":"1","key":"731_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/cid\/ciz728","volume":"71","author":"HM Garcia Garrido","year":"2020","unstructured":"Garcia Garrido HM, Mak AMR, Wit F, Wong GWM, Knol MJ, Vollaard A, et al. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting. Clin Infect Dis. 2020;71(1):41\u201350. https:\/\/doi.org\/10.1093\/cid\/ciz728.","journal-title":"Clin Infect Dis"},{"key":"731_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fpubh.2018.00070","volume":"6","author":"NB Erdmann","year":"2018","unstructured":"Erdmann NB, Prentice HA, Bansal A, Wiener HW, Burkholder G, Shrestha S, et al. Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy. Front Public Health. 2018;6:70. https:\/\/doi.org\/10.3389\/fpubh.2018.00070.","journal-title":"Front Public Health"},{"issue":"8","key":"731_CR11","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/cit937","volume":"58","author":"S Kern\u00e9is","year":"2014","unstructured":"Kern\u00e9is S, Launay O, Turbelin C, Batteux F, Hanslik T, Bo\u00eblle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(8):1130\u20139. https:\/\/doi.org\/10.1093\/cid\/cit937.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"731_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.amjmed.2018.12.011","volume":"132","author":"F El Chaer","year":"2019","unstructured":"El Chaer F, El Sahly HM. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. Am J Med. 2019;132(4):437\u201346. https:\/\/doi.org\/10.1016\/j.amjmed.2018.12.011.","journal-title":"Am J Med"},{"issue":"4","key":"731_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","volume":"71","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among US Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109\u201317. https:\/\/doi.org\/10.15585\/mmwr.mm7104a1.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"36","key":"731_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","volume":"73","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among US Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7336a3.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"731_CR15","unstructured":"Loehr J (2024) Pneumococcal Vaccines [Presentation Slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta GA. https:\/\/stacks.cdc.gov\/view\/cdc\/157883 June 27, 2024. Accessed October 1, 2024."},{"key":"731_CR16","unstructured":"Kobayashi M (2024) Preliminary Work Group Interpretations of EtR and Next Steps: PCV-21 [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta GA. https:\/\/stacks.cdc.gov\/view\/cdc\/157880\/cdc_157880_DS1.pdf February 29, 2024. Accessed October 1, 2024."},{"key":"731_CR17","unstructured":"Spach D (2024) National HIV Curriculum: Basic HIV Primary Care. Immunizations in Adults\u2014Pneumococcal Vaccination. https:\/\/www.hiv.uw.edu\/custom\/primary-care\/immunizations\/11 2024. Accessed December 12, 2024"},{"key":"731_CR18","doi-asserted-by":"publisher","first-page":"100576","DOI":"10.1016\/j.eclinm.2020.100576","volume":"29\u201330","author":"HMG Garrido","year":"2020","unstructured":"Garrido HMG, Schnyder JL, Tanck MWT, Vollaard A, Spijker R, Grobusch MP, et al. Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis. EClinicalMedicine. 2020;29\u201330:100576. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100576.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"731_CR19","doi-asserted-by":"publisher","first-page":"106629","DOI":"10.1016\/j.ijantimicag.2022.106629","volume":"60","author":"HM Garcia Garrido","year":"2022","unstructured":"Garcia Garrido HM, Schnyder JL, Haydari B, Vollaard AM, Tanck MWT, de Bree GJ, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy. Int J Antimicrob Agents. 2022;60(2):106629. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106629.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"731_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/qad.0000000000003126","volume":"36","author":"L Mohapi","year":"2022","unstructured":"Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, Ratanasuwan W, Molina JM, et al. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. AIDS. 2022;36(3):373\u201382. https:\/\/doi.org\/10.1097\/qad.0000000000003126.","journal-title":"AIDS"},{"key":"731_CR21","unstructured":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7). ClinicalTrials.gov. NCT05393037. https:\/\/clinicaltrials.gov\/study\/NCT05393037 Updated July 25, 2024. Accessed August 12, 2024."},{"issue":"1","key":"731_CR22","doi-asserted-by":"publisher","first-page":"ofad696","DOI":"10.1093\/ofid\/ofad696","volume":"11","author":"KC Rudmann","year":"2024","unstructured":"Rudmann KC, Cooper G, Marjuki H, Reingold A, Barnes M, Petit S, et al. Meningococcal Disease in Persons With HIV Reported Through Active Surveillance in the United States, 2009\u20132019. Open Forum Infect Dis. 2024;11(1):ofad696. https:\/\/doi.org\/10.1093\/ofid\/ofad696.","journal-title":"Open Forum Infect Dis."},{"issue":"4","key":"731_CR23","doi-asserted-by":"publisher","first-page":"ofw226","DOI":"10.1093\/ofid\/ofw226","volume":"3","author":"CM Harris","year":"2016","unstructured":"Harris CM, Wu HM, Li J, Hall HI, Lee A, Zell E, et al. Meningococcal Disease in Patients With Human Immunodeficiency Virus Infection: A Review of Cases Reported Through Active Surveillance in the United States, 2000\u20132008. Open Forum Infect Dis. 2016;3(4):ofw226. https:\/\/doi.org\/10.1093\/ofid\/ofw226.","journal-title":"Open Forum Infect Dis."},{"issue":"24","key":"731_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.15585\/mmwr.mm7224a4","volume":"72","author":"AB Rubis","year":"2023","unstructured":"Rubis AB, Howie RL, Marasini D, Sharma S, Marjuki H, McNamara LA. Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(24):663\u20134. https:\/\/doi.org\/10.15585\/mmwr.mm7224a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"731_CR25","unstructured":"Centers for Disease Control and Prevention. National Center for Immunization and Respiratory Diseases Report: Enhanced Meningococcal Disease Surveillance, 2022. https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2022-508.pdf April 8, 2024. Accessed October 1, 2024."},{"key":"731_CR26","unstructured":"Centers for Disease Control and Prevention. Health Alert Network Archive - 00505. Increase in Invasive Serogroup Y Meningococcal Disease in the United States. https:\/\/emergency.cdc.gov\/han\/2024\/han00505.asp#:~:text=Based%20on%20updated%20surveillance%20data,who%20previously%20received%20MenACWY%20vaccine. Published March 28, 2024. Accessed October 1, 2024."},{"key":"731_CR27","unstructured":"National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. . https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection Updated November 12, 2024. Accessed December 11, 2024."},{"issue":"4","key":"731_CR28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","volume":"161","author":"J Lujan-Zilbermann","year":"2012","unstructured":"Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012;161(4):676-81.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2012.04.005.","journal-title":"J Pediatr"},{"issue":"9","key":"731_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/hiv.13495","volume":"24","author":"C Isitt","year":"2023","unstructured":"Isitt C, Bartolf A, Andrews N, Athaide S, Pryce-Williams R, Townsend-Payne K, et al. The propositive study: Immunogenicity and safety of a four-component recombinant protein-based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV. HIV Med. 2023;24(9):979\u201389. https:\/\/doi.org\/10.1111\/hiv.13495.","journal-title":"HIV Med"},{"issue":"15","key":"731_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","volume":"73","author":"JP Collins","year":"2024","unstructured":"Collins JP, Crowe SJ, Ortega-Sanchez IR, Bahta L, Campos-Outcalt D, Loehr J, et al. Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged \u226510 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345\u201350. https:\/\/doi.org\/10.15585\/mmwr.mm7315a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"731_CR31","unstructured":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults. ClinicalTrials.gov ID: NCT04502693. https:\/\/clinicaltrials.gov\/study\/NCT04502693 Updated March 5, 2024. Accessed August 12, 2024."},{"issue":"10102","key":"731_CR32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/s0140-6736(17)31449-6","volume":"390","author":"H Petousis-Harris","year":"2017","unstructured":"Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(17)31449-6.","journal-title":"Lancet"},{"issue":"6","key":"731_CR33","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1097\/olq.0000000000001793","volume":"50","author":"WE Abara","year":"2023","unstructured":"Abara WE, Bernstein KT, Lewis FMT, Pathela P, Islam A, Eberhart M, et al. Healthy Vaccinee Bias and MenB-FHbp Vaccine Effectiveness Against Gonorrhea. Sex Transm Dis. 2023;50(6):e8\u201310. https:\/\/doi.org\/10.1097\/olq.0000000000001793.","journal-title":"Sex Transm Dis"},{"issue":"3","key":"731_CR34","doi-asserted-by":"publisher","first-page":"106225","DOI":"10.1016\/j.jinf.2024.106225","volume":"89","author":"B Wang","year":"2024","unstructured":"Wang B, Mohammed H, Andraweera P, McMillan M, Marshall H. Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis. J Infect. 2024;89(3):106225. https:\/\/doi.org\/10.1016\/j.jinf.2024.106225.","journal-title":"J Infect"},{"issue":"5","key":"731_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/olq.0000000000001771","volume":"50","author":"AR Raccagni","year":"2023","unstructured":"Raccagni AR, Galli L, Spagnuolo V, Bruzzesi E, Muccini C, Bossolasco S, et al. Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study. Sex Transm Dis. 2023;50(5):247\u201351. https:\/\/doi.org\/10.1097\/olq.0000000000001771.","journal-title":"Sex Transm Dis"},{"issue":"9","key":"731_CR36","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/s1473-3099(24)00031-8","volume":"24","author":"SN Ladhani","year":"2024","unstructured":"Ladhani SN, White PJ, Campbell H, Mandal S, Borrow R, Andrews N, et al. Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK. Lancet Infect Dis. 2024;24(9):e576\u201383. https:\/\/doi.org\/10.1016\/s1473-3099(24)00031-8.","journal-title":"Lancet Infect Dis"},{"key":"731_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(24)00236-6","author":"JM Molina","year":"2024","unstructured":"Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 \u00d7 2 factorial design. Lancet Infect Dis. 2024. https:\/\/doi.org\/10.1016\/s1473-3099(24)00236-6.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"731_CR38","doi-asserted-by":"publisher","first-page":"e081675","DOI":"10.1136\/bmjopen-2023-081675","volume":"14","author":"KL Seib","year":"2024","unstructured":"Seib KL, Donovan B, Thng C, Lewis DA, McNulty A, Fairley CK, et al. Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol. BMJ Open. 2024;14(4):e081675. https:\/\/doi.org\/10.1136\/bmjopen-2023-081675.","journal-title":"BMJ Open"},{"key":"731_CR39","doi-asserted-by":"publisher","first-page":"S243","DOI":"10.1093\/infdis\/jiad532","volume":"229","author":"J O'Shea","year":"2024","unstructured":"O\u2019Shea J, Zucker J, Stampfer S, Cash-Goldwasser S, Minhaj FS, Dretler A, et al. Prolonged Mpox Disease in People With Advanced HIV: Characterization of Mpox Skin Lesions. J Infect Dis. 2024;229:S243-s8. https:\/\/doi.org\/10.1093\/infdis\/jiad532.","journal-title":"J Infect Dis."},{"issue":"9","key":"731_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.15585\/mmwr.mm7209a4","volume":"72","author":"AK Rao","year":"2023","unstructured":"Rao AK, Schrodt CA, Minhaj FS, Waltenburg MA, Cash-Goldwasser S, Yu Y, et al. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023. MMWR Morb Mortal Wkly Rep. 2023;72(9):232\u201343. https:\/\/doi.org\/10.15585\/mmwr.mm7209a4.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"731_CR41","unstructured":"Centers for Disease Control and Prevention. Health Alert Network Archieve - 00475. Severe Manifestations of Monkeypox among People who are Immunocompromised Due to HIV or Other Conditions. https:\/\/emergency.cdc.gov\/han\/2022\/han00475.asp September 29, 2022. Accessed November 10, 2024."},{"issue":"44","key":"731_CR42","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.15585\/mmwr.mm7144e1","volume":"71","author":"MJ Miller","year":"2022","unstructured":"Miller MJ, Cash-Goldwasser S, Marx GE, Schrodt CA, Kimball A, Padgett K, et al. Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(44):1412\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7144e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"731_CR43","doi-asserted-by":"publisher","first-page":"460","DOI":"10.15585\/mmwr.mm7320a3","volume":"73","author":"SAJ Guagliardo","year":"2024","unstructured":"Guagliardo SAJ, Kracalik I, Carter RJ, Braden C, Free R, Hamal M, et al. Monkeypox Virus Infections After 2 Preexposure Doses of JYNNEOS Vaccine - United States, May 2022-May 2024. MMWR Morb Mortal Wkly Rep. 2024;73(20):460\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm7320a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"731_CR44","unstructured":"Centers for Disease Control and Prevention. Mpox vaccination overview for healthcare professionals. Interim Clinical Considerations for Use of Vaccine for Mpox Prevention in the United States. https:\/\/www.cdc.gov\/mpox\/hcp\/vaccine-considerations\/vaccination-overview.html November 25, 2024. Accessed November 27, 2024."},{"issue":"2","key":"731_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/m23-3269","volume":"177","author":"N Murthy","year":"2024","unstructured":"Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Recommended Adult Immunization Schedule, United States, 2024. Ann Intern Med. 2024;177(2):221\u201337. https:\/\/doi.org\/10.7326\/m23-3269.","journal-title":"Ann Intern Med"},{"key":"731_CR46","unstructured":"Centers for Disease Control and Prevention. Health Alert Network Archive - 00516. Prevention Strategies for Mpox, including Vaccinating People at Risk via Sexual Exposure, for U.S. Travelers Visiting Countries with Clade I Mpox Outbreaks. https:\/\/emergency.cdc.gov\/han\/2024\/han00516.asp September 23, 2024. Accessed November 9, 2024."},{"issue":"11","key":"731_CR47","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1016\/j.vaccine.2020.01.058","volume":"38","author":"ET Overton","year":"2020","unstructured":"Overton ET, Lawrence SJ, Stapleton JT, Weidenthaler H, Schmidt D, Koenen B, et al. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine. 2020;38(11):2600\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.058.","journal-title":"Vaccine"},{"issue":"2","key":"731_CR48","doi-asserted-by":"publisher","first-page":"ofv040","DOI":"10.1093\/ofid\/ofv040","volume":"2","author":"ET Overton","year":"2015","unstructured":"Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, et al. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis. 2015;2(2):ofv040. https:\/\/doi.org\/10.1093\/ofid\/ofv040.","journal-title":"Open Forum Infect Dis."},{"issue":"5","key":"731_CR49","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/infdis\/jis753","volume":"207","author":"RN Greenberg","year":"2013","unstructured":"Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis. 2013;207(5):749\u201358. https:\/\/doi.org\/10.1093\/infdis\/jis753.","journal-title":"J Infect Dis"},{"issue":"20","key":"731_CR50","doi-asserted-by":"publisher","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","volume":"72","author":"AF Dalton","year":"2023","unstructured":"Dalton AF, Diallo AO, Chard AN, Moulia DL, Deputy NP, Fothergill A, et al. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(20):553\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7220a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"731_CR51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/cid\/ciae181","volume":"79","author":"EAG Faherty","year":"2024","unstructured":"Faherty EAG, Holly T, Ogale YP, Spencer H, Becht AM, Crisler G, et al. Investigation of an Mpox Outbreak Affecting Many Vaccinated Persons in Chicago, Illinois-March 2023-June 2023. Clin Infect Dis. 2024;79(1):122\u20139. https:\/\/doi.org\/10.1093\/cid\/ciae181.","journal-title":"Clin Infect Dis"},{"key":"731_CR52","unstructured":"Rao A (2023) Considerations for long-term protection against mpox [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta GA. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-06-21-23\/04-mpox-Rao-508.pdf June 21, 2023. Accessed November 27, 2024."},{"key":"731_CR53","unstructured":"JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo. ClinicalTrials.gov ID: NCT02977715. https:\/\/clinicaltrials.gov\/study\/NCT02977715 Updated April 9, 2024. Accessed November 10, 2024."},{"issue":"6","key":"731_CR54","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11904-023-00670-0","volume":"20","author":"MA Corcorran","year":"2023","unstructured":"Corcorran MA, Kim HN. Strategies for Hepatitis B Virus Prevention in People Living with HIV. Curr HIV\/AIDS Rep. 2023;20(6):451\u20137. https:\/\/doi.org\/10.1007\/s11904-023-00670-0.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"731_CR55","doi-asserted-by":"publisher","first-page":"745541","DOI":"10.3389\/fimmu.2021.745541","volume":"12","author":"Y Tian","year":"2021","unstructured":"Tian Y, Hua W, Wu Y, Zhang T, Wang W, Wu H, et al. Immune Response to Hepatitis B Virus Vaccine Among People Living With HIV: A Meta-Analysis. Front Immunol. 2021;12:745541. https:\/\/doi.org\/10.3389\/fimmu.2021.745541.","journal-title":"Front Immunol"},{"issue":"5","key":"731_CR56","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11904-019-00461-6","volume":"16","author":"PD Farooq","year":"2019","unstructured":"Farooq PD, Sherman KE. Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV. Curr HIV\/AIDS Rep. 2019;16(5):395\u2013403. https:\/\/doi.org\/10.1007\/s11904-019-00461-6.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"731_CR57","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/cid\/ciad201","volume":"77","author":"KM Marks","year":"2023","unstructured":"Marks KM, Kang M, Umbleja T, Avihingsanon A, Sugandhavesa P, Cox AL, et al. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Na\u00efve People With Human Immunodeficiency Virus. Clin Infect Dis. 2023;77(3):414\u20138. https:\/\/doi.org\/10.1093\/cid\/ciad201.","journal-title":"Clin Infect Dis"},{"key":"731_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24490","author":"KM Marks","year":"2024","unstructured":"Marks KM, Kang M, Umbleja T, Cox A, Vigil KJ, Ta NT, et al. HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.24490.","journal-title":"JAMA"},{"issue":"7","key":"731_CR59","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.vaccine.2012.12.047","volume":"31","author":"VB Lopes","year":"2013","unstructured":"Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040\u20134. https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.047.","journal-title":"Vaccine"},{"issue":"11","key":"731_CR60","doi-asserted-by":"publisher","first-page":"e2027577","DOI":"10.1001\/jamanetworkopen.2020.27577","volume":"3","author":"K Bruxvoort","year":"2020","unstructured":"Bruxvoort K, Slezak J, Huang R, Ackerson B, Sy LS, Qian L, et al. Association of Number of Doses With Hepatitis B Vaccine Series Completion in US Adults. JAMA Netw Open. 2020;3(11):e2027577. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.27577.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"731_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6905a1","volume":"69","author":"NP Nelson","year":"2020","unstructured":"Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69(5):1\u201338. https:\/\/doi.org\/10.15585\/mmwr.rr6905a1.","journal-title":"MMWR Recomm Rep"},{"issue":"97","key":"731_CR62","first-page":"645","volume":"50","author":"World Health Organization (WHO)","year":"2022","unstructured":"World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper (2022 update). Wkly Epidemiol Rec. 2022;50(97):645\u201372.","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"731_CR63","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ijc.33185","volume":"148","author":"GM Clifford","year":"2021","unstructured":"Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 2021;148(1):38\u201347. https:\/\/doi.org\/10.1002\/ijc.33185.","journal-title":"Int J Cancer"},{"issue":"9","key":"731_CR64","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/cid\/ciy274","volume":"67","author":"TJ Wilkin","year":"2018","unstructured":"Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, et al. A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018;67(9):1339\u201346. https:\/\/doi.org\/10.1093\/cid\/ciy274.","journal-title":"Clin Infect Dis"},{"key":"731_CR65","doi-asserted-by":"publisher","first-page":"101585","DOI":"10.1016\/j.eclinm.2022.101585","volume":"52","author":"L Staadegaard","year":"2022","unstructured":"Staadegaard L, R\u00f6nn MM, Soni N, Bellerose ME, Bloem P, Brisson M, et al. Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;52:101585. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101585.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"731_CR66","doi-asserted-by":"publisher","first-page":"2016007","DOI":"10.1080\/21645515.2021.2016007","volume":"18","author":"E Meites","year":"2022","unstructured":"Meites E, Wilkin TJ, Markowitz LE. Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States. Hum Vaccin Immunother. 2022;18(1):2016007. https:\/\/doi.org\/10.1080\/21645515.2021.2016007.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"731_CR67","doi-asserted-by":"publisher","first-page":"EVIDoa2100056","DOI":"10.1056\/EVIDoa2100056","volume":"1","author":"RV Barnabas","year":"2022","unstructured":"Barnabas RV, Brown ER, Onono MA, Bukusi EA, Njoroge B, Winer RL, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022;1(5):EVIDoa2100056. https:\/\/doi.org\/10.1056\/EVIDoa2100056.","journal-title":"NEJM Evid."},{"key":"731_CR68","doi-asserted-by":"publisher","first-page":"102368","DOI":"10.1016\/j.pmedr.2023.102368","volume":"35","author":"DE Waheed","year":"2023","unstructured":"Waheed DE, Burdier FR, Eklund C, Baussano I, Mariz FC, T\u00e9blick L, et al. An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report. Prev Med Rep. 2023;35:102368. https:\/\/doi.org\/10.1016\/j.pmedr.2023.102368.","journal-title":"Prev Med Rep"},{"issue":"2","key":"731_CR69","doi-asserted-by":"publisher","first-page":"e059968","DOI":"10.1136\/bmjopen-2021-059968","volume":"12","author":"D Machalek","year":"2022","unstructured":"Machalek D, Rees H, Chikandiwa A, Munthali R, Travill D, Mbulawa Z, et al. Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before-after design. BMJ Open. 2022;12(2):e059968. https:\/\/doi.org\/10.1136\/bmjopen-2021-059968.","journal-title":"BMJ Open"},{"issue":"1","key":"731_CR70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.japh.2023.10.028","volume":"64","author":"SE Villemure","year":"2024","unstructured":"Villemure SE, Wilby KJ. A systematic review of the treatment of active anogenital warts with human papillomavirus vaccines. J Am Pharm Assoc (2003). 2024;64(1):179\u201385. https:\/\/doi.org\/10.1016\/j.japh.2023.10.028.","journal-title":"J Am Pharm Assoc (2003)."},{"key":"731_CR71","doi-asserted-by":"publisher","unstructured":"Fouda I, Mohammed HAK, Mohammed GMY (2024) Intralesional Quadrivalent Human Papilloma Virus Vaccine Versus Candida Antigen in the Treatment of Multiple Recalcitrant Non-Genital Warts. Dermatol Pract Concept 14(2). https:\/\/doi.org\/10.5826\/dpc.1402a66.","DOI":"10.5826\/dpc.1402a66"},{"issue":"7","key":"731_CR72","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1093\/cid\/ciaa1456","volume":"73","author":"C Firnhaber","year":"2021","unstructured":"Firnhaber C, Swarts A, Jezile V, Mulongo M, Goeieman B, Williams S, et al. Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus: A Randomized, Double-blind. Placebo-controlled Trial Clin Infect Dis. 2021;73(7):e2211\u20136. https:\/\/doi.org\/10.1093\/cid\/ciaa1456.","journal-title":"Placebo-controlled Trial Clin Infect Dis"},{"issue":"11","key":"731_CR73","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/jcm10112300","volume":"10","author":"HC Ku","year":"2021","unstructured":"Ku HC, Tsai YT, Konara-Mudiyanselage SP, Wu YL, Yu T, Ko NY. Incidence of Herpes Zoster in HIV-Infected Patients Undergoing Antiretroviral Therapy: A Systematic Review and Meta-analysis. J Clin Med. 2021;10(11):2300. https:\/\/doi.org\/10.3390\/jcm10112300.","journal-title":"J Clin Med."},{"issue":"8","key":"731_CR74","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","volume":"211","author":"EM Berkowitz","year":"2015","unstructured":"Berkowitz EM, Moyle G, Stellbrink HJ, Sch\u00fcrmann D, Kegg S, Stoll M, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279\u201387. https:\/\/doi.org\/10.1093\/infdis\/jiu606.","journal-title":"J Infect Dis"},{"issue":"1","key":"731_CR75","doi-asserted-by":"publisher","first-page":"2341456","DOI":"10.1080\/21645515.2024.2341456","volume":"20","author":"V Carta","year":"2024","unstructured":"Carta V, Mangeri L, Tiecco G, Foc\u00e0 E, Quiros-Roldan E, De Francesco MA. Immunogenicity and safety of live attenuated and recombinant\/inactivated varicella zoster vaccines in people living with HIV: A systematic review. Hum Vaccin Immunother. 2024;20(1):2341456. https:\/\/doi.org\/10.1080\/21645515.2024.2341456.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"731_CR76","doi-asserted-by":"publisher","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, et al. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination. Open Forum Infect Dis. 2022;9(10):ofac485. https:\/\/doi.org\/10.1093\/ofid\/ofac485.","journal-title":"Open Forum Infect Dis."},{"issue":"4","key":"731_CR77","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jinf.2017.06.007","volume":"75","author":"J Moyes","year":"2017","unstructured":"Moyes J, Walaza S, Pretorius M, Groome M, von Gottberg A, Wolter N, et al. Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting. J Infect. 2017;75(4):346\u201355. https:\/\/doi.org\/10.1016\/j.jinf.2017.06.007.","journal-title":"J Infect"},{"key":"731_CR78","unstructured":"U.S. Food & Drug Administration. FDA Requires Guillain-Barr\u00e9 Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy.\u00a02025.\u00a0https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and. Accessed 17 Feb 2025."},{"issue":"32","key":"731_CR79","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","volume":"73","author":"A Britton","year":"2024","unstructured":"Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, et al. Use of Respiratory Syncytial Virus Vaccines in Adults Aged \u226560 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696\u2013702. https:\/\/doi.org\/10.15585\/mmwr.mm7332e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"16","key":"731_CR80","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, P\u00e9rez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023;388(16):1465\u201377. https:\/\/doi.org\/10.1056\/NEJMoa2213836.","journal-title":"N Engl J Med"},{"key":"731_CR81","unstructured":"Das R. Update on Moderna\u2019s RSV Vaccine, mRESVIA (mRNA-1345), in adults \u226560 years of age [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta GA. https:\/\/stacks.cdc.gov\/view\/cdc\/157864 June 26, 2024. . Accessed August 28, 2024."},{"issue":"7","key":"731_CR82","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023;388(7):595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2209604.","journal-title":"N Engl J Med"},{"issue":"13","key":"731_CR83","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jama.2024.15775","volume":"332","author":"D Surie","year":"2024","unstructured":"Surie D, Self WH, Zhu Y, Yuengling KA, Johnson CA, Grijalva CG, et al. RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older. JAMA. 2024;332(13):1105\u20137. https:\/\/doi.org\/10.1001\/jama.2024.15775.","journal-title":"JAMA"},{"issue":"6","key":"731_CR84","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1093\/cid\/ciae010","volume":"78","author":"MG Ison","year":"2024","unstructured":"Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, et al. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024;78(6):1732\u201344. https:\/\/doi.org\/10.1093\/cid\/ciae010.","journal-title":"Clin Infect Dis"},{"key":"731_CR85","unstructured":"Pfizer. Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO for RSV in Older Adults [Press Release]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-top-line-data-full-season-two February 29, 2024. Accessed August 28, 2024."},{"issue":"21","key":"731_CR86","doi-asserted-by":"publisher","first-page":"489","DOI":"10.15585\/mmwr.mm7321a3","volume":"73","author":"AM Hause","year":"2024","unstructured":"Hause AM, Moro PL, Baggs J, Zhang B, Marquez P, Melgar M, et al. Early Safety Findings Among Persons Aged \u226560 Years Who Received a Respiratory Syncytial Virus Vaccine - United States, May 3, 2023-April 14, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(21):489\u201394. https:\/\/doi.org\/10.15585\/mmwr.mm7321a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"731_CR87","unstructured":"Lloyd P. Evaluation of Guillain-Barr\u00e9 Syndrome (GBS) following Respiratory Syncytial Virus (RSV) Vaccination Among Adults 65 Years and Older [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta GA. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/05-RSV-Adult-Lloyd-508.pdf October 23\u201324, 2024. Accessed December 11, 2024."},{"issue":"5","key":"731_CR88","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11904-022-00618-w","volume":"19","author":"MA Spinelli","year":"2022","unstructured":"Spinelli MA, Jones BLH, Gandhi M. COVID-19 Outcomes and Risk Factors Among People Living with HIV. Curr HIV\/AIDS Rep. 2022;19(5):425\u201332. https:\/\/doi.org\/10.1007\/s11904-022-00618-w.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"7","key":"731_CR89","doi-asserted-by":"publisher","first-page":"e1964","DOI":"10.1093\/cid\/ciaa1339","volume":"73","author":"D Dandachi","year":"2021","unstructured":"Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, et al. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019. Clin Infect Dis. 2021;73(7):e1964\u201372. https:\/\/doi.org\/10.1093\/cid\/ciaa1339.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"731_CR90","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10238-022-00840-1","volume":"23","author":"X Han","year":"2023","unstructured":"Han X, Hou H, Xu J, Ren J, Li S, Wang Y, et al. Significant association between HIV infection and increased risk of COVID-19 mortality: a meta-analysis based on adjusted effect estimates. Clin Exp Med. 2023;23(3):689\u2013700. https:\/\/doi.org\/10.1007\/s10238-022-00840-1.","journal-title":"Clin Exp Med"},{"issue":"11","key":"731_CR91","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/s2352-3018(21)00239-3","volume":"8","author":"X Yang","year":"2021","unstructured":"Yang X, Sun J, Patel RC, Zhang J, Guo S, Zheng Q, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021;8(11):e690\u2013700. https:\/\/doi.org\/10.1016\/s2352-3018(21)00239-3.","journal-title":"Lancet HIV"},{"issue":"3","key":"731_CR92","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/coh.0000000000000791","volume":"18","author":"KW Miller","year":"2023","unstructured":"Miller KW, Gandhi RT. The severity of COVID-19 across the spectrum of HIV. Curr Opin HIV AIDS. 2023;18(3):119\u201325. https:\/\/doi.org\/10.1097\/coh.0000000000000791.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"731_CR93","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/qai.0000000000003378","volume":"95","author":"VT Nguyen","year":"2024","unstructured":"Nguyen VT, Nagavedu K, Morrison M, Chen T, Randall LM, Landazabal C, et al. COVID-19 Severity in People With HIV Compared With Those Without HIV. J Acquir Immune Defic Syndr. 2024;95(5):479\u201385. https:\/\/doi.org\/10.1097\/qai.0000000000003378.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"731_CR94","doi-asserted-by":"publisher","first-page":"e2236397","DOI":"10.1001\/jamanetworkopen.2022.36397","volume":"5","author":"R Lang","year":"2022","unstructured":"Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, et al. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Netw Open. 2022;5(10):e2236397. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36397.","journal-title":"JAMA Netw Open"},{"key":"731_CR95","doi-asserted-by":"publisher","first-page":"1297195","DOI":"10.3389\/fimmu.2024.1297195","volume":"15","author":"GA Yendewa","year":"2024","unstructured":"Yendewa GA, Perez JA, Patil N, McComsey GA. Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study. Front Immunol. 2024;15:1297195. https:\/\/doi.org\/10.3389\/fimmu.2024.1297195.","journal-title":"Front Immunol"},{"key":"731_CR96","unstructured":"Centers for Disease Control and Prevention. Vaccines and Immunizations: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html Updated October 31, 2024. Accessed December 12, 2024."},{"key":"731_CR97","unstructured":"Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization of Pemgarda (Pemivibart). https:\/\/www.fda.gov\/media\/177067\/download?attachment Updated September 2024. Accessed August 28, 2024."},{"key":"731_CR98","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1017\/s095026882300153x","volume":"151","author":"T Zhao","year":"2023","unstructured":"Zhao T, Yang Z, Wu Y, Yang J. Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis. Epidemiol Infect. 2023;151:e176. https:\/\/doi.org\/10.1017\/s095026882300153x.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"731_CR99","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/hiv.13537","volume":"25","author":"MH S\u00f8ndergaard","year":"2024","unstructured":"S\u00f8ndergaard MH, Thavarajah JJ, Churchill Henson H, Wejse CM. SARS-CoV-2 vaccine immunogenicity for people living with HIV: A systematic review and meta-analysis. HIV Med. 2024;25(1):16\u201337. https:\/\/doi.org\/10.1111\/hiv.13537.","journal-title":"HIV Med"},{"issue":"8","key":"731_CR100","doi-asserted-by":"publisher","first-page":"180","DOI":"10.15585\/mmwr.mm7308a5","volume":"73","author":"J DeCuir","year":"2024","unstructured":"DeCuir J, Payne AB, Self WH, Rowley EAK, Dascomb K, DeSilva MB, et al. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged \u226518 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024;73(8):180\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm7308a5.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"1","key":"731_CR101","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/vaccines12010083","volume":"12","author":"MD Rousculp","year":"2024","unstructured":"Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, et al. Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study. Vaccines (Basel). 2024;12(1):83. https:\/\/doi.org\/10.3390\/vaccines12010083.","journal-title":"Vaccines (Basel)."},{"issue":"12","key":"731_CR102","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1086\/320747","volume":"32","author":"AD Fine","year":"2001","unstructured":"Fine AD, Bridges CB, De Guzman AM, Glover L, Zeller B, Wong SJ, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32(12):1784\u201391. https:\/\/doi.org\/10.1086\/320747.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"731_CR103","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3201\/eid1911.130546","volume":"19","author":"C Cohen","year":"2013","unstructured":"Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009\u20132011. Emerg Infect Dis. 2013;19(11):1766\u201374. https:\/\/doi.org\/10.3201\/eid1911.130546.","journal-title":"Emerg Infect Dis"},{"issue":"Suppl 1","key":"731_CR104","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.1093\/cid\/ciq036","volume":"52","author":"PJ Peters","year":"2011","unstructured":"Peters PJ, Skarbinski J, Louie JK, Jain S, Roland M, Jani SG, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1)\u2013United States, spring and summer 2009. Clin Infect Dis. 2011;52(Suppl 1):S183\u20138. https:\/\/doi.org\/10.1093\/cid\/ciq036.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"731_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","volume":"73","author":"LA Grohskopf","year":"2024","unstructured":"Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024\u201325 Influenza Season. MMWR Recomm Rep. 2024;73(5):1\u201325. https:\/\/doi.org\/10.15585\/mmwr.rr7305a1.","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"731_CR106","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/qad.0000000000001774","volume":"32","author":"S Pallikkuth","year":"2018","unstructured":"Pallikkuth S, De Armas LR, Pahwa R, Rinaldi S, George VK, Sanchez CM, et al. Impact of aging and HIV infection on serologic response to seasonal influenza vaccination. AIDS. 2018;32(9):1085\u201394. https:\/\/doi.org\/10.1097\/qad.0000000000001774.","journal-title":"AIDS"},{"issue":"26","key":"731_CR107","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1016\/s0264-410x(00)00079-7","volume":"18","author":"FP Kroon","year":"2000","unstructured":"Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18(26):3040\u20139. https:\/\/doi.org\/10.1016\/s0264-410x(00)00079-7.","journal-title":"Vaccine"},{"issue":"24","key":"731_CR108","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2302099","volume":"389","author":"A Hsiao","year":"2023","unstructured":"Hsiao A, Yee A, Fireman B, Hansen J, Lewis N, Klein NP. Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med. 2023;389(24):2245\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2302099.","journal-title":"N Engl J Med"},{"issue":"4","key":"731_CR109","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"CJ Wei","year":"2020","unstructured":"Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov. 2020;19(4):239\u201352. https:\/\/doi.org\/10.1038\/s41573-019-0056-x.","journal-title":"Nat Rev Drug Discov"},{"key":"731_CR110","unstructured":"World Health Organization (WHO). Ten threats to global health in 2019. https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019 January 16, 2019. Accessed September 5, 2024."},{"issue":"3","key":"731_CR111","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/vaccines10030424","volume":"10","author":"R Shrestha","year":"2022","unstructured":"Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, et al. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines (Basel). 2022;10(3):424. https:\/\/doi.org\/10.3390\/vaccines10030424.","journal-title":"Vaccines (Basel)."},{"issue":"7","key":"731_CR112","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s10461-024-04351-w","volume":"28","author":"M Pereira","year":"2024","unstructured":"Pereira M, Santos Aleluia IR, de Castro CT, de Almeida OT, Cunha MS, Magno L, et al. COVID-19 Vaccine Acceptance and Hesitancy among People Living with HIV: Review and Meta-Analysis. AIDS Behav. 2024;28(7):2193\u2013204. https:\/\/doi.org\/10.1007\/s10461-024-04351-w.","journal-title":"AIDS Behav"},{"issue":"10","key":"731_CR113","doi-asserted-by":"publisher","first-page":"e004206","DOI":"10.1136\/bmjgh-2020-004206","volume":"5","author":"SL Wilson","year":"2020","unstructured":"Wilson SL, Wiysonge C. Social media and vaccine hesitancy. BMJ Glob Health. 2020;5(10):e004206. https:\/\/doi.org\/10.1136\/bmjgh-2020-004206.","journal-title":"BMJ Glob Health."},{"issue":"15","key":"731_CR114","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1016\/j.vaccine.2023.03.008","volume":"41","author":"A Srivastav","year":"2023","unstructured":"Srivastav A, Lu PJ, Amaya A, Dever JA, Stanley M, Franks JL, et al. Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018. Vaccine. 2023;41(15):2572\u201381. https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.008.","journal-title":"Vaccine"},{"issue":"2","key":"731_CR115","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/qai.0000000000003243","volume":"94","author":"AD Castel","year":"2023","unstructured":"Castel AD, Barth S, Wilbourn BC, Horberg M, Monroe AK, Greenberg AE. Trends in COVID-19 Vaccine Hesitancy and Uptake Among Persons Living With HIV in Washington. DC J Acquir Immune Defic Syndr. 2023;94(2):124\u201334. https:\/\/doi.org\/10.1097\/qai.0000000000003243.","journal-title":"DC J Acquir Immune Defic Syndr"},{"issue":"3","key":"731_CR116","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.mayocp.2020.12.024","volume":"96","author":"LJ Finney Rutten","year":"2021","unstructured":"Finney Rutten LJ, Zhu X, Leppin AL, Ridgeway JL, Swift MD, Griffin JM, et al. Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy. Mayo Clin Proc. 2021;96(3):699\u2013707. https:\/\/doi.org\/10.1016\/j.mayocp.2020.12.024.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"731_CR117","doi-asserted-by":"publisher","first-page":"ofaa428","DOI":"10.1093\/ofid\/ofaa428","volume":"7","author":"L Rearigh","year":"2020","unstructured":"Rearigh L, O\u2019Neill J, Kubat M, Sayles H, Swindells S, Bares SH. Surprisingly Low Levels of Measles Immunity in Persons With HIV: A Seroprevalence Survey in a United States HIV Clinic. Open Forum Infect Dis. 2020;7(10):ofaa428. https:\/\/doi.org\/10.1093\/ofid\/ofaa428.","journal-title":"Open Forum Infect Dis."},{"issue":"2","key":"731_CR118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83\u2013100. https:\/\/doi.org\/10.1038\/s41577-020-00479-7.","journal-title":"Nat Rev Immunol"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00731-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00731-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00731-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:05:46Z","timestamp":1769605546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00731-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00731-6","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"7 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fiona Gispen declares that she has no conflict of interest. Kristen Marks has received grants from Gilead Sciences and consulted for Gilead Sciences (expert witness), Immorna (Data safety monitoring), and Novo Nordisk (Data safety monitoring).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"17"}}